SC
VRDN icon

Stephens Consulting’s Viridian Therapeutics VRDN Stock Holding History

Stephens Consulting’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25
Closed -$337 – 1998
2025
Q1 		$337 Buy
+25
New +$426 ﹤0.01% 1400

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Stephens Consulting's VRDN Position: Q2 2025 in Review

Stephens Consulting sold out of Viridian Therapeutics (VRDN) in Q2 2025, closing a stake of 25 shares — an estimated $337 sold.

Stephens Consulting first reported a position in VRDN in Q1 2025 and held it in 1 quarter. The position peaked at $337 in Q1 2025. 170 funds tracked by Wall St. Rank hold VRDN as of Q2 2025.

  • Stephens Consulting reported no remaining Viridian Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 25 Viridian Therapeutics shares in Q2 2025, an estimated $337.
  • Stephens Consulting first reported a position in Viridian Therapeutics in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Viridian Therapeutics position peaked at $337 in Q1 2025.
  • 170 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.